Approved by the FDA, EMA, and other regulatory agencies, upadacitinib (Rinvoq) treats chronic inflammatory diseases such as RA, psoriatic arthritis, and ulcerative colitis by inhibiting JAK1, disrupting cytokine signaling. Here, JAK1 is linked to rheumatoid arthritis.